MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback